Oculis secures USD 100 million to advance its neuroprotective treatment pipeline
Life sciences
17 February 2025
Oculis develops innovative ophthalmic and neuroprotective treatments to address unmet medical needs in eye care and neuro-ophthalmic diseases.
Vaud-based biopharma Oculis has successfully completed an oversubscribed USD 100 million offering, further strengthening its pipeline of innovative ophthalmic and neuro-ophthalmic treatments.
Oculis Holding AG, a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, has raised USD 100 million in an oversubscribed offering of 5,000,000 ordinary shares at USD 20.00 per share. This financing follows the company’s USD 59 million direct offering in April 2024, further reinforcing its market position after its dual listing on NASDAQ and NASDAQ Iceland.
The proceeds will be used to advance and accelerate Oculis’s clinical development pipeline, particularly the development of Privosegtor (OCS-05), a novel neuroprotective candidate for acute optic neuritis with potential applications in other neuro-ophthalmic diseases. Additionally, the funding will support working capital and general corporate purposes.
The offering is expected to close on 18 February 2025, subject to customary closing conditions. Prior to closing, the new shares will be issued from the company’s existing capital band, bringing its total number of registered shares to 53,943,700.
BofA Securities and Leerink Partners acted as joint bookrunning managers for the offering, with Pareto Securities as lead manager and Arctica Finance as financial advisor. The offering was made pursuant to a previously filed registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC).
Next-generation treatments for vision-related disorders
Oculis has emerged as a leading innovator in ophthalmic treatments, with a pipeline that includes OCS-01, a topical eye drop for diabetic macular edema, Privosegtor (OCS-05) for neuroprotection, and Licaminlimab (OCS-02), an anti-TNFα candidate for dry eye disease. Headquartered in Switzerland with operations in the United States and Iceland, Oculis continues to attract strong international healthcare investment.
With this latest funding milestone, Oculis is set to accelerate its clinical trials and regulatory advancements, solidifying its role in developing next-generation treatments for vision-related disorders.
